文献速递消化道肿瘤放疗放疗物理与技术

FOLFIRINOX后立体定向放疗治疗局部晚期胰腺癌的II期长期结果

A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
PubMed 文献 · Radiother Oncol · 2020-11-17

LAPC-1多中心II期研究纳入50例组织学证实的不可手术局部晚期胰腺癌患者,诱导8周期FOLFIRINOX后无进展者接受40 Gy/5次SBRT。全组1年、3年OS分别为62%和10%;SBRT组中位OS 18个月 vs 非SBRT组5个月(p<0.001);7例术后根治性切除,切除组3年OS 43% vs 未切除组6.5%(p=0.03)。

要点

  • FOLFIRINOX后SBRT在LAPC中显示长期生存,全组3年OS为10%。
  • SBRT组中位OS 18个月,显著优于非SBRT组的5个月(p<0.001)。
  • 7例实现根治性切除,切除组3年OS 43%显著优于未切除组6.5%。

核心结论

  • LAPC患者接受FOLFIRINOX后SBRT可获得长期生存,并提高根治性手术概率,切除患者生存显著优于未切除者。

研究设计与样本

  • 多中心II期研究(LAPC-1),纳入组织学证实的初诊不可手术LAPC患者。
  • 诱导8周期FOLFIRINOX,无疾病进展者接受SBRT总剂量40 Gy分5次。

主要发现

  • 共纳入50例,因化疗期间疾病进展11例,最终39例接受FOLFIRINOX后SBRT。
  • 全组1年和3年OS分别为62%和10%,中位随访13个月。
  • SBRT组中位OS 18个月(95%CI 13.2-21.5),非SBRT组5个月(95%CI 4.1-6.7),p<0.001。
  • 放化疗后7例接受手术并实现根治性切除,切除组3年OS 43% vs 未切除组6.5%(p=0.03)。
  • SBRT期间4例出现≥3级不良事件。

关键数值与推荐

  • SBRT总剂量40 Gy分5次,用于FOLFIRINOX后无疾病进展的LAPC患者。

临床怎么用

  • 对初诊不可手术LAPC,可考虑FOLFIRINOX诱导后无进展者行SBRT,并评估根治性手术可能性。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the long-term outcome of a multicenter phase II study with FOLFIRINOX followed by stereotactic body radiotherapy (LAPC-1 trial) in patients with locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Patients with histological confirmation of LAPC inoperable at diagnosis were enrolled. Induction therapy with 8 cycles of FOLFIRINOX was administered. If no disease progression was found after chemotherapy, patients received stereotactic body radiotherapy (SBRT) at a total dose of 40 Gy in 5 fractions. RESULTS: In LAPC-1 trial, 50 patients were included, but due to disease progression in 11 patients under chemotherapy, 39 patients received stereotactic SBRT after FOLFIRINOX treatment. In whole population, the 1- and 3-year overall survival (OS) were 62% and 10%, respectively. Median follow-up was 13 months. The SBRT group had median OS of 18 months (95% CI 13.2-21.5) versus 5 months (95% CI 4.1-6.7) in non-SBRT group (p<0.001). After chemoradiotherapy, seven patients underwent surgery achieving a radical resection. Patients who underwent surgery had a 3-years OS of 43% compared to 6.5% in the unresected group (p=0.03). Four patients developed grade ≥ 3 adverse events during SBRT. CONCLUSIONS: Long-term survival has been found in patients with LAPC underwent FOLFIRINOX followed by SBRT. This approach increased the probability of a radical surgery. The resected patients achieved a significant better survival compared to unresected group.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Teriaca MA, Loi M, Suker M, et al. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Radiother Oncol. 2020. PMID: 33217500. doi:10.1016/j.radonc.2020.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。